An Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis

NCT03557281 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

76

Enrollment

INDUSTRY

Sponsor class

Conditions

Tuberculosis

Interventions

DRUG: GSK3036656
DRUG: Rifafour e-275

Sponsor

GlaxoSmithKline